TuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a report issued on Friday, May 16th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.56) per share for the year. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for TuHURA Biosciences' FY2026 earnings at ($0.52) EPS.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
TuHURA Biosciences Stock Performance
HURA traded down $0.18 during trading hours on Monday, hitting $2.83. 110,925 shares of the stock were exchanged, compared to its average volume of 243,796. The stock has a 50-day simple moving average of $3.78 and a 200-day simple moving average of $4.03. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.93.
Hedge Funds Weigh In On TuHURA Biosciences
Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in TuHURA Biosciences during the first quarter worth $69,000. Apollon Wealth Management LLC lifted its stake in TuHURA Biosciences by 86.0% in the first quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company's stock valued at $371,000 after buying an additional 53,154 shares during the last quarter. Sabal Trust CO bought a new stake in TuHURA Biosciences in the first quarter valued at $127,000. Jefferies Financial Group Inc. bought a new stake in TuHURA Biosciences in the fourth quarter valued at $54,000. Finally, Squarepoint Ops LLC bought a new stake in TuHURA Biosciences in the fourth quarter valued at $223,000. 0.62% of the stock is currently owned by institutional investors.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
